arrow
J

Je-Jung Lee

chonnam national university hwasun hospital
H指数:42
被引数:9,601

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study

移植不适格多发性骨髓瘤患者中硼替佐米维持治疗在VMP诱导后的真实世界有效性:一项目标试验模拟研究

2026-03-230
OAAI
Novel Wearable-Based Real-Time Temperature Monitoring in Hospitals for Febrile Adverse Events in Patients with Cancer: A Prospective Feasibility Study

基于可穿戴设备的医院实时体温监测在癌症患者发热性不良反应中的应用:一项前瞻性可行性研究

2025-11-210
OAAI
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803)

一项多中心前瞻性II期研究,评估利妥昔单抗联合硼替佐米、来那度胺和地塞米松,随后给予来那度胺维持治疗(R-VRD)在瓦尔登斯特罗姆巨球蛋白血症患者中的疗效(KMM1803)。

2025-11-010
PRE
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)

随机化III期研究:比较泊马利度胺联合环磷酰胺、地塞米松与泊马利度胺联合地塞米松治疗复发或难治性骨髓瘤的疗效——一项亚洲骨髓瘤网络研究(AMN003)

2025-10-060
OA
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study (Sept, 10.1007/s00277-024-05958-8, 2024)
2024-09-230
OAAI
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
2024-09-041
OAAI
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
2024-06-061
OAAI
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia

2022欧洲白血病风险分层对急性髓系白血病的验证

2024-04-124
OAAI
Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis

接受selinexor和地塞米松治疗的广泛预处理的多发性骨髓瘤患者的真实世界结果: 韩国多中心回顾性分析

2024-01-250
PRE
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study
2024-01-181
OAAI
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

白消安加美法仑与大剂量美法仑作为具有高风险特征的多发性骨髓瘤自体干细胞移植的预处理方案 (KMM 2015)

2023-07-012
PRE